ABL1 methylation in Ph-positive ALL is exclusively associated with the P210 form of BCR-ABL

被引:17
|
作者
Shteper, PJ
Siegfried, Z
Asimakopoulos, FA
Palumbo, GA
Rachmilewitz, EA
Ben-Neriah, Y
Ben-Yehuda, D
机构
[1] Hadassah Univ Hosp, Dept Hematol, IL-91120 Jerusalem, Israel
[2] Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Immunol, IL-91010 Jerusalem, Israel
[3] Univ Catania, Dept Hematol, Catania, Italy
基金
以色列科学基金会;
关键词
acute lymphoblastic leukemia; chronic myeloid leukemia; Philadelphia chromosome; ABL; methylation;
D O I
10.1038/sj.leu.2402026
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In human Ph-positive leukemia there is a clear association of different forms of the BCR-ABL oncogene with distinct types of leukemia. The P190 form of BCR-ABL is rarely observed in chronic myeloid leukemia (CML) but is present in 50% of Ph-positive acute lymphoblastic leukemia (ALL). In contrast, the P210 form is observed both in CML and 50% of Ph-positive ALL. Methylation of the proximal promoter of the ABL1 gene has been shown to he a nearly universal event associated with clinical progression of CML. This raises the question of whether methylation of the ABL1 promoter is an epigenetic modification also associated with Ph-positive ALL. To study this issue, we used methylation-specific PCR and bisulfite sequencing to determine the methylation status of the ABL1 promoter in 18 Ph-positive ALL samples. We report here that gene-specific ABL1 promoter methylation is associated mainly with the P210 form of BCR-ABL and not the P190 form. While six out of the seven P210-positive ALL samples had ABL1 promoter methylation, none of the 11 P190-positive ALL samples demonstrated ABL1 promoter methylation. In addition, we estimated the extent and relative abundance of ABL1 promoter methylation in several Ph-positive ALL samples and compared it to the methylation pattern in chronic, accelerated and blastic crisis phases of CML. We put forth a model that correlates the different types of leukemias with the different levels of ABL1 promoter methylation.
引用
收藏
页码:575 / 582
页数:8
相关论文
共 50 条
  • [21] All common p210 and p190 Bcr-abl variants can be targeted by RNA interference
    L Wohlbold
    H van der Kuip
    A Moehring
    G Granot
    M Oren
    H-P Vornlocher
    W E Aulitzky
    Leukemia, 2005, 19 : 290 - 292
  • [22] CTLs specific for bcr-abl joining region segment peptides fail to lyse leukemia cells expressing p210 bcr-abl protein
    Chen, W
    Qin, HL
    Reese, VA
    Cheever, MA
    JOURNAL OF IMMUNOTHERAPY, 1998, 21 (04): : 257 - 268
  • [23] Conventional Western blotting techniques will not reliably quantify p210 BCR-ABL - Response
    Copland, Mhairi
    Hamilton, Ashley
    Holyoake, Tessa L.
    BLOOD, 2007, 109 (03) : 1336 - 1336
  • [24] Glucose transport regulation by p210 Bcr-Abl in a chronic myeloid leukaemia model
    Bentley, J
    Walker, I
    McIntosh, E
    Whetton, AD
    Owen-Lynch, PJ
    Baldwin, SA
    BRITISH JOURNAL OF HAEMATOLOGY, 2001, 112 (01) : 212 - 215
  • [25] P210 BCR-ABL IS COMPLEXED TO P160 BCR AND PH-P53 PROTEINS IN K562 CELLS
    CAMPBELL, ML
    LI, WJ
    ARLINGHAUS, RB
    ONCOGENE, 1990, 5 (05) : 773 - 776
  • [26] Activation of p65 NF-kappa B protein by p210(BCR-ABL) in myeloid cell line (p210(BCR-ABL) activates p65 NF-kappa B)
    Hamdane, M
    DavidCordonnier, MH
    DHalluin, JC
    ONCOGENE, 1997, 15 (19) : 2267 - 2275
  • [28] Analysis of the biologic properties of p230 Bcr-Abl reveals unique and overlapping properties with the oncogenic p185 and p210 Bcr-Abl tyrosine kinases
    Quackenbush, RC
    Reuther, GW
    Miller, JP
    Courtney, KD
    Pear, WS
    Pendergast, AM
    BLOOD, 2000, 95 (09) : 2913 - 2921
  • [29] Bcr-Abl P210 fails to inhibit apoptosis in U937 cells.
    Ahmed, A
    Duprez, I
    Novault, S
    Solary, E
    Vainchenker, W
    Varet, V
    Turhan, AG
    BLOOD, 1996, 88 (10) : 813 - 813
  • [30] LOW-LEVELS OF P190 BCR-ABL MESSENGER-RNA ARE DETECTABLE IN PATIENTS WITH CHRONIC PHASE P210 CML AND P210 ALL
    VANRHEE, F
    HOCHHAUS, A
    LIN, F
    GOLDMAN, JM
    CROSS, NCP
    EXPERIMENTAL HEMATOLOGY, 1995, 23 (08) : 922 - 922